Skip to main content
Premium Trial:

Request an Annual Quote

GlaxoSmithKline Will Use Fluidigm s Microfluidic Chips

NEW YORK, Feb. 14 - Fluidigm Corporation will provide microfluidic platform technology, tools, software and customized microfluidic prototype chips for GlaxoSmithKline, the company said.

 

Terms of the deal call for GSK to use Fluidigm's multi-layer soft lithography technology in pharmaceutical development.

 

Fluidigm said in a statement on Monday that its platform will allow GSK researchers to redesign chips very quickly-in a matter of weeks, rather than months.

 

For its part, the pharma giant is working to accelerate drug development by developing microfluidic instruments that are highly automated and can work with small sample volumes.

 

Financial details of the agreement were not disclosed.

 

Fluidigm, based in South San Francisco, Calif., develops lab-on-a-chip technology. It has invented a sandwiched rubber chip with built-in microfluidics for applications in mixing and cell sorting and mixing, and intend to adapt the technology for use in protein separation, sample preparation, and single molecule analysis.

 

The firm signed an agreement with Axon Instruments in July 2001 to develop a cell capture and microfluidics chip for drug discovery.

The Scan

Booster Push

New data shows a decline in SARS-CoV-2 vaccine efficacy over time, which the New York Times says Pfizer is using to argue its case for a booster, even as the lower efficacy remains high.

With Help from Mr. Fluffington, PurrhD

Cats could make good study animals for genetic research, the University of Missouri's Leslie Lyons tells the Atlantic.

Man Charged With Threatening to Harm Fauci, Collins

The Hill reports that Thomas Patrick Connally, Jr., was charged with making threats against federal officials.

Nature Papers Present Approach to Find Natural Products, Method to ID Cancer Driver Mutations, More

In Nature this week: combination of cryogenic electron microscopy with genome mining helps uncover natural products, driver mutations in cancer, and more.